David F. Wurtman
Director/Board Member bij GlycoMira Therapeutics, Inc.
Profiel
David F.
Wurtman was the founder of Lyric Pharmaceuticals, Inc. (founded in 2013), where he held the titles of President, Chief Executive Officer & Director from 2013 to 2018.
He is currently a Director at GlycoMira Therapeutics, Inc. Dr. Wurtman's former positions include Principal at Protein Design Labs, Inc. and Genzyme Corp., Vice President-International Business at ChinaBio LLC, Executive Vice President-Strategic Projects at PAVmed, Inc., Principal at EOS Biotechnology, Inc., and VP-Medical Affairs & Product Development at Kineta, Inc. (Washington).
He was also the Chief Medical Officer at Lucid Diagnostics, Inc. from 2019 to 2022.
Dr. Wurtman holds an MBA from Massachusetts Institute of Technology and a doctorate from Harvard Mit Health Sciences & Technology.
Actieve functies van David F. Wurtman
Bedrijven | Functie | Begin |
---|---|---|
GlycoMira Therapeutics, Inc.
GlycoMira Therapeutics, Inc. BiotechnologyHealth Technology GlycoMira Therapeutics, Inc. is a preclinical-stage biopharmaceutical company based in Salt Lake City, UT. The private company is dedicated to improving the standard of care and outcomes for patients with cancer and other inflammatory diseases. GlycoMira is developing a new class of innate immune system modulators based on polysaccharides that naturally occur within the body. The company's lead drug candidate, GM-1111, has demonstrated potential to address unmet needs in solid tumor treatment and supportive care. The CEO of the company is William P. Tew. | Director/Board Member | - |
Eerdere bekende functies van David F. Wurtman
Bedrijven | Functie | Einde |
---|---|---|
LUCID DIAGNOSTICS INC. | Chief Tech/Sci/R&D Officer | 31-03-2022 |
Lyric Pharmaceuticals, Inc.
Lyric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA. | Founder | 01-08-2018 |
Kineta, Inc. (Washington)
Kineta, Inc. (Washington) Pharmaceuticals: MajorHealth Technology Kineta, Inc. engages in the development of novel immuno-therapies. It develops a pipeline of therapies that address critical unmet patient needs in oncology, chronic pain and biodefense. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Seattle, WA. | Chief Tech/Sci/R&D Officer | - |
PAVMED INC. | Corporate Officer/Principal | - |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Corporate Officer/Principal | - |
Opleiding van David F. Wurtman
Massachusetts Institute of Technology | Masters Business Admin |
Harvard Mit Health Sciences & Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
PAVMED INC. | Health Technology |
LUCID DIAGNOSTICS INC. | Health Technology |
Bedrijven in privébezit | 7 |
---|---|
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
ChinaBio LLC
ChinaBio LLC Financial ConglomeratesFinance ChinaBio LLC operates as an investment, consulting and media company which helps life science companies. It organizes life science investment and partnering conferences in China. The firm’s conferences comprise investor forums, partnering forums, executive workshops and SEED business plan competitions. It also offers consulting services, including China strategy development, market and competitive intelligence, technology survey and search, partnering arrangement, CRO and CMO selection, management, business strategy, funding strategy, assistance, collaboration agreements, in-licensing, out-licensing, the United States operations consulting services, investment analysis, due diligence and portfolio analysis. The company serves executives, entrepreneurs, investors, pharma and multinational companies. ChinaBio was founded in April 2007 by Greg B. Scott and James W. Larrick and is headquartered in Shanghai, China. | Finance |
Lyric Pharmaceuticals, Inc.
Lyric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA. | Health Technology |
EOS Biotechnology, Inc.
EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California. | Health Technology |
Kineta, Inc. (Washington)
Kineta, Inc. (Washington) Pharmaceuticals: MajorHealth Technology Kineta, Inc. engages in the development of novel immuno-therapies. It develops a pipeline of therapies that address critical unmet patient needs in oncology, chronic pain and biodefense. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Seattle, WA. | Health Technology |
GlycoMira Therapeutics, Inc.
GlycoMira Therapeutics, Inc. BiotechnologyHealth Technology GlycoMira Therapeutics, Inc. is a preclinical-stage biopharmaceutical company based in Salt Lake City, UT. The private company is dedicated to improving the standard of care and outcomes for patients with cancer and other inflammatory diseases. GlycoMira is developing a new class of innate immune system modulators based on polysaccharides that naturally occur within the body. The company's lead drug candidate, GM-1111, has demonstrated potential to address unmet needs in solid tumor treatment and supportive care. The CEO of the company is William P. Tew. | Health Technology |